Nanochon | Ben Holmes
An episode of the MedTech Jam Session with Chris and Mike D podcast, hosted by Mike Donoghue and Chris Lyons, titled "Nanochon | Ben Holmes" was published on April 21, 2025 and runs 45 minutes.
April 21, 2025 ·45m · MedTech Jam Session with Chris and Mike D
Summary
Tackling one of the biggest challenges in orthopedics [Cartilage Repair], Benjamin Holmes, CEO of Nanochon, shares his story from the early days of academic research to the often harsh realities of leading a startup. Here’s what we learned from Ben: 1. Nanochon is developing a next-generation implantable device for cartilage repair—offering an early intervention alternative to knee replacement for active patients suffering from joint pain and cartilage loss. 2. Fundraising Masterclass! Hear how Ben raised nearly $10 million—including non-dilutive grants and angel funding—while staying lean, navigating market downturns, and prioritizing milestone-based fundraising over dilution worries. 3. Build a clear clinical roadmap. With strong large-animal data behind them, Nanochon is preparing for its first-in-human safety study in Canada, setting the stage for a pivotal randomized trial to support FDA approval and future commercialization. For more information, visit Nanochon.com.Jam with us wherever you get your podcasts! AppleSpotify
Episode Description
Tackling one of the biggest challenges in orthopedics [Cartilage Repair], Benjamin Holmes, CEO of Nanochon, shares his story from the early days of academic research to the often harsh realities of leading a startup. Here’s what we learned from Ben:
1. Nanochon is developing a next-generation implantable device for cartilage repair—offering an early intervention alternative to knee replacement for active patients suffering from joint pain and cartilage loss.
2. Fundraising Masterclass! Hear how Ben raised nearly $10 million—including non-dilutive grants and angel funding—while staying lean, navigating market downturns, and prioritizing milestone-based fundraising over dilution worries.
3. Build a clear clinical roadmap. With strong large-animal data behind them, Nanochon is preparing for its first-in-human safety study in Canada, setting the stage for a pivotal randomized trial to support FDA approval and future commercialization.
For more information, visit Nanochon.com.
Jam with us wherever you get your podcasts!